None listed
Conditions
Brief summary
The aim of this study (registry) is to document diagnosis, treatment and outcomes for patients with advanced melanoma over time, in order to better understand survival and treatment efficacy in these patients. Who is it for? You may be eligible for this study if you are aged 18 years or older, and have been diagnosed with stage III or IV cutaneous or unknown primary melanoma. Study details Information regarding the multi-disciplinary management of melanoma, including surgery, radiotherapy, systemic therapy, and palliative care in the routine clinical practice setting is obtained via medical records. Information regarding the clinical outcomes of treatment, including time to disease progression and overall survival, will also be collected. Participants will be followed up for a minimum of 12 months and a maximum of 5 years, if funding for this extension can be secured. No additional tests or time commitment by participants is required. It is hoped that this study will allow a comprehensive analysis of melanoma diagnosis, treatment and outcomes, supporting much needed basic, translational and clinical research of this disease. This may help to provide insight into optimal management of advanced melanoma in light of new and emerging treatments.
Interventions
The follow up period is a minimum of 12 months (and up to 5 years) with extension dependent on funding of registry. Follow up frequency is approximately every 3-6 months. No additional tests are required. The project will capture data from the medical record of patients with histological or cytological confirmed stage III or IV melanoma from January 2020 onwards, from HREC approved sites within Australasia. Information regarding the multi-disciplinary management of melanoma will be collected,
The follow up period is a minimum of 12 months (and up to 5 years) with extension dependent on funding of registry. Follow up frequency is approximately every 3-6 months. No additional tests are required. The project will capture data from the medical record of patients with histological or cytological confirmed stage III or IV melanoma from January 2020 onwards, from HREC approved sites within Australasia. Information regarding the multi-disciplinary management of melanoma will be collected, including surgery, radiotherapy, systemic therapy and palliative care in the routine clinical practice setting.
Sponsors
The Walter and Eliza Hall Institute of Medical Research
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with stage III or IV cutaneous or unknown primary melanoma 2. Aged 18 years or above at diagnosis
Exclusion criteria
None
Outcome results
None listed